Novartis Services, Inc.
Industry / private company
Location:
Cambridge, MA,
United States (USA) (US)
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison (2023)
Rugo HSS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SMM, Cardoso F, Bardia A, et al.
Journal article
Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2 (2022)
Jhaveri K, O'Shaughnessy J, Fasching P, Cardoso F, Tolaney S, Hamilton E, Sharma VK, et al.
Conference contribution